Seidl C. Targets for therapy of bladder cancer. Semin Nucl Med. 2020;50:162–70.

Article  PubMed  Google Scholar 

Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404–23.

Article  PubMed  Google Scholar 

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019;16:465–83.

Article  CAS  PubMed  Google Scholar 

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharm. 2014;740:364–78.

Article  CAS  Google Scholar 

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.

Article  CAS  PubMed  Google Scholar 

Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. J Am Med Assoc. 2020;324:1980–91.

Article  CAS  Google Scholar 

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36:3353–60.

Article  CAS  PubMed  Google Scholar 

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–56.e525.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kardoust Parizi M, Margulis V, Lotan Y, Mori K, Shariat SF. Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urol Oncol. 2021;39:409–21.

Article  CAS  PubMed  Google Scholar 

van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?(dagger). Eur Urol. 2020;78:682–7.

Article  PubMed  Google Scholar 

Xie X, Lin J, Zhong Y, Fu M, Tang A. FGFR(3S249C) mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. Exp Ther Med. 2019;18:1226–34.

CAS  PubMed  PubMed Central  Google Scholar 

Hong JH, Tong ZJ, Wei TE, Lu YC, Huang CY, Huang CY, et al. Cigarette smoke containing acrolein contributes to cisplatin resistance in human bladder cancers through the regulation of HER2 pathway or FGFR3 pathway. Mol Cancer Ther. 2022;21:1010–9.

Article  CAS  PubMed  Google Scholar 

Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharm. 2020;13:1–6.

Article  CAS  Google Scholar 

Ni SJ, Zhao LQ, Wang XF, Wu ZH, Hua RX, Wan CH, et al. CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-kappaB-miR-21 pathways. J Hematol Oncol. 2018;11:17.

Article  PubMed  PubMed Central  Google Scholar 

Huang Z, Yan Y, Zhu Z, Liu J, He X, Dalangood S, et al. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell Death Dis. 2021;12:537.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Z, Liu J, Yang J, Yan Y, Yang C, He X, et al. PDE4B induces epithelial-to-mesenchymal transition in bladder cancer cells and is transcriptionally suppressed by CBX7. Front Cell Dev Biol. 2021;9:783050.

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Wang H, Jian C, Li W, Ye K, Ren J, et al. The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC. Int J Biol Sci. 2022;18:2132–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren W, Ren J, Zhang N, Liu X, Deng Y, Jiang Y, et al. CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. Biochem Biophys Res Commun. 2022;613:12–18.

Article  CAS  PubMed  Google Scholar 

Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-kappaB activation and PD-L1 expression. Mol Cell. 2019;73:22–35.e26.

Article  CAS  PubMed  Google Scholar 

Yi L, Wang H, Li W, Ye K, Xiong W, Yu H, et al. The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer. Cell Death Dis. 2021;12:944.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, et al. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 2018;19:e46255.

Zhang T, Gong Y, Meng H, Li C, Xue L. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor. Clin Epigenet. 2020;12:72.

Article  CAS  Google Scholar 

Taylor-Papadimitriou J, Burchell JM. Histone methylases and demethylases regulating antagonistic methyl marks: changes occurring in cancer. Cells. 2022;11:1113.

Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.

Article  PubMed  PubMed Central  Google Scholar 

Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007;26:5889–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaensch ES, Zhu J, Cochrane JC, Marr SK, Oei TA, Damle M, et al. A Polycomb domain found in committed cells impairs differentiation when introduced into PRC1 in pluripotent cells. Mol Cell. 2021;81:4677–91.e4678.

Article  CAS  PubMed  Google Scholar 

Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 2013;31:398–406.

Article  CAS  PubMed  Google Scholar 

Mao W, Huang X, Wang L, Zhang Z, Liu M, Li Y, et al. Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res. 2019;38:169.

Article  PubMed  PubMed Central  Google Scholar 

Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204.

Article  PubMed  Google Scholar 

Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.

Article  CAS  PubMed  Google Scholar 

Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 2006;25:7381–90.

Article  CAS  PubMed  Google Scholar 

Zhao J, Tan W, Zhang L, Liu J, Shangguan M, Chen J, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharm. 2021;190:114536.

Article  CAS  PubMed  Google Scholar 

Chen L, Zhang Y, Yin L, Cai B, Huang P, Li X, et al. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J Exp Clin Cancer Res. 2021;40:345.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bae JH, Schlessinger J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol Cells. 2010;29:443–8.

Article  CAS  PubMed  Google Scholar 

Nakamura IT, Kohsaka S, Ikegami M, Ikeuchi H, Ueno T, Li K, et al. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis Oncol. 2021;5:66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kacew A, Sweis RF. FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer. Front Immunol. 2020;11:575258.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491–5.

Article  CAS  PubMed  Google Scholar 

Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114–29.

Article  CAS  PubMed